Participants with diabetic macular edema treated with a senolytic Bcl-xL inhibitor in the phase 2 BEHOLD study experienced visual acuity improvement after 18 weeks, according to a press release from Unity Biotechnology.
The study enrolled 65 participants who were actively treated with anti-VEGF therapy and had a visual acuity deficit and residual retinal fluid.
After a single injection of UBX1325, participants experienced a mean improvement in best corrected visual acuity of 6.1 letters from baseline at 18 weeks compared with 1.1 letters in participants treated with sham (P = .0368)…..
Read more: https://www.healio.com/news/ophthalmology/20220812/positive-phase-2-study-results-reported-for-dme-treatment?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=214789326967
Source: Helio